New drug MG2512 enters human trials for Hard-to-Treat cancers
NCT ID NCT07348653
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study is testing a new drug called MG2512 in about 116 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also watch for any signs that the drug might shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MG2512 injection
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 116 participants, focused on safety and dosing. It is too soon to know if MG2512 will be effective, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sichuan Cancer Hospital
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact